Moderna's head of oncology leaves to helm new Cambridge cancer biotech Oncorus

The head of oncology at Moderna Therapeutics leaving the $7 billion biotech company to lead small Cambridge cancer startup Oncorus Inc., the startup announced Wednesday. Ted Ashburn's exit comes as the Moderna is finishing construction on its new personalized cancer vaccine unit in Norwood and preparing to move nearly two dozen highly anticipated messenger RNA programs through clinical trials. Moderna has 11 preclinical programs with another 10 in clinical trails, including one that has entered…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news